Sarepta Therapeutics Registers Offer of Up to 4.8M Shares of Common Stock -8K

On September 18, 2012, Sarepta Therapeutics

registered the offer and sale up to 4,848,430 shares of its common stock issuable upon the exercise of currently outstanding warrants, including up to 891,385 shares of common stock that are issuable upon the exercise of warrants originally issued on December 19, 2007 (the "December 2007 warrants"), 34,626 shares of common stock that are issuable upon the exercise of a warrant originally issued on March 20, 2008 (the "March 2008 warrant"), 2,354,034 shares of common stock that are issuable upon the exercise of warrants originally issued on January 30, 2009 (the "January 2009 warrants") and 1,568,385 shares of common stock that are issuable upon the exercise of warrants originally issued on August 25, 2009 (the "August 2009 warrants"). The December 2007 warrants were issued pursuant to a prospectus dated November 22, 2006 and a prospectus supplement dated December 12, 2007. Each December 2007 warrant is exercisable at any time on or prior to December 18, 2012 at an exercise price of $14.70 per share. The March 2008 warrant was issued in connection with the acquisition of Ercole Biotechnology, Inc., or Ercole, in exchange for an outstanding warrant issued by Ercole. The March 2008 warrant is exercisable at any time until November 13, 2012 at an exercise price of $21.66 per share. The January 2009 warrants were issued pursuant to a prospectus dated November 22, 2006 and a prospectus supplement dated January 30, 2009. Each January 2009 warrant is exercisable at any time on or prior to July 30, 2014 at an exercise price of $6.96 per share. The August 2009 warrants were issued pursuant to a prospectus dated August 13, 2009 and a prospectus supplement dated August 20, 2009. Each August 2009 warrant is exercisable at any time on or prior to August 25, 2014 at an exercise price of $10.68 per share. The Company will receive the proceeds from any cash exercises of the warrants. The Company intends to use the net proceeds from this offering, if any, for general corporate purposes, including the continued development of eteplirsen and other product candidates.